文献速递中枢神经肿瘤放疗放疗物理与技术

调强放疗与容积旋转调强放疗治疗胶质母细胞瘤:剂量学优势是否带来临床获益

Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage?
PubMed 文献 · Adv Radiat Oncol · 2018-09-28

该研究回顾性分析了2014至2015年间在一家机构接受治疗的88例病理确诊的胶质母细胞瘤患者,其中45例接受调强放疗(IMRT),43例接受容积旋转调强放疗(VMAT)。中位随访27个月时,两组的总生存、无进展生存及无新发或加重毒性反应率均无显著差异(log-rank检验P值分别为.33、.87和.23);IMRT组野外失败更多(P=.02);VMAT组平均治疗时间较IMRT组显著缩短29%(10.3分钟 vs 14.6分钟,P<.01)。作者认为VMAT可获得与IMRT相似的肿瘤学和毒性结局,并可能通过缩短治疗时间改善资源利用,VMAT应被视为胶质母细胞瘤患者的潜在放疗模式。

要点

  • VMAT与IMRT治疗胶质母细胞瘤的总生存、无进展生存及毒性反应率无显著差异。
  • IMRT组野外失败模式更多(P=.02)。
  • VMAT平均治疗时间较IMRT显著缩短29%(10.3分钟 vs 14.6分钟,P<.01)。

核心结论

  • 对于胶质母细胞瘤,VMAT治疗可获得与IMRT相似的肿瘤学和毒性结局,并可能通过缩短治疗时间改善资源利用。
  • 作者认为VMAT应被视为胶质母细胞瘤患者的潜在放疗模式。

研究设计与样本

  • 回顾性连续纳入2014至2015年间在一家机构病理确诊的胶质母细胞瘤患者,该时期涵盖从IMRT向VMAT的过渡。
  • 术后放疗采用VMAT(2至3个共面弧,加或不加非共面弧)或IMRT(5至6个机架角),同期及辅助替莫唑胺化疗。
  • 采用Kaplan-Meier法进行生存分析。

主要发现

  • 共纳入88例患者,其中IMRT组45例,VMAT组43例;两组在年龄、性别、体能状态、切除范围及高剂量靶区体积方面相似。
  • 中位随访27个月(范围0.7-32.3个月),总生存、无进展生存及无新发或加重毒性反应率在两组间无差异(log-rank检验P值分别为.33、.87和.23)。
  • 放疗期间脱发、红斑、恶心、新发或加重乏力、头痛的发生率,以及因血小板减少或中性粒细胞减少而降低替莫唑胺剂量的发生率,两组间均无差异(所有P>.05)。
  • IMRT组野外失败更多(P=.02),失败模式存在差异。
  • VMAT组平均治疗时间较IMRT组显著缩短29%(VMAT组平均10.3分钟 vs IMRT组平均14.6分钟,P<.01)。

临床怎么用

  • 作者认为VMAT应被视为胶质母细胞瘤患者的潜在放疗模式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Volumetric modulated arc therapy (VMAT) has been shown by multiple planning studies to hold dosimetric advantages over intensity modulated radiation therapy (IMRT) in the management of brain tumors, including glioblastoma (GBM). Although promising, the clinical impact of these findings has not been fully elucidated. METHODS AND MATERIALS: We retrospectively reviewed consecutive patients with a pathologic-confirmed diagnosis of GBM who were treated between 2014 and 2015, a period that encompassed the transition from IMRT to VMAT at a single institution. After surgery, radiation with VMAT consisted of 2 to 3 coplanar arcs with or without an additional noncoplanar arc or IMRT with 5 to 6 gantry angles with concurrent and adjuvant temozolomide. Actuarial analyses were performed using the Kaplan Meier method. RESULTS: A total of 88 patients treated with IMRT (n = 45) and VMAT (n = 43) were identified. Patients were similar in terms of age, sex, performance status, extent of resection, and the high dose target volume. At a median follow-up time of 27 months (range, .7-32.3 months), the overall survival, freedom from progression, and freedom from new or worsening toxicity rates were not different between the 2 treatment groups (log-rank: P = .33; .87; and .23, respectively). There was no difference in incidences of alopecia, erythema, nausea, worsening or new onset fatigue, or headache during radiation, or temozolomide dose reduction for thrombocytopenia or neutropenia (all P > .05). Patterns of failure were different with more out of field failures in the IMRT group (P = .02). The mean time of treatment (TOT) was significantly reduced by 29% (P < .01) with VMAT (mean TOT: 10.3 minutes) compared with IMRT (mean TOT: 14.6 minutes). CONCLUSIONS: For GBM, treatment with VMAT results in similar oncologic and toxicity outcomes compared with IMRT and may improve resource utilization by reducing TOT. VMAT should be considered a potential radiation modality for patients with GBM.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sheu T, Briere TM, Olanrewaju AM, et al. Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage? Adv Radiat Oncol. 2018. PMID: 30706010. doi:10.1016/j.adro.2018.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。